The company manufactures and sells shoe uppers primarily for industrial or export-oriented clients and earns significant revenue from leasing out commercial real estate properties.
The company lacks a durable competitive advantage as evidenced by extremely low ROCE (3.2%) and ROE (0.7%). While it has a real estate leasing arm, the manufacturing segment is a low-margin commodity business with declining revenues, and the high concentration of related-party sales suggests no independent pricing power.
Management has prioritized maintaining a large balance of low-yielding loans and advances to related parties (over 13,500 Lacs) rather than reinvesting in high-return operations or returning capital to shareholders. No dividends have been paid despite reported profits, and the capital is largely trapped in non-operating assets.
The investment collapsed as the company's balance sheet was hollowed out by its role as a captive financier for related parties. The massive, interest-free loans to Focus Energy Limited were never repaid, eventually requiring a total write-off that wiped out the equity base. Meanwhile, the core manufacturing business continued its slow decay, unable to compete without reinvestment, and the rental income was diverted to cover administrative overhead and promoter interests rather than reaching minority shareholders.
RichFakir rates Phoenix International Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Phoenix International Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Phoenix International Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Phoenix International Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →